Affinity constructs and affinity molecules to direct insecticidal toxins to insect specific structures of target insects are presented herein. The affinity constructs comprise of at least one affinity molecule that is capable of recognizing, or capable of binding to, or binding to, or being directed to, or being designed to bind to an insect-specific structure in and/or on a target insect, and at least one other affinity molecule capable of binding to, or binding to, or being directed to, or being designed to bind to an insecticidal protein (toxin) wherein the at least two affinity molecules are operably coupled. Presented herein are also methods of making and using these affinity constructs and affinity molecules.

The transgenic plants expressing one or more antagonist IL-10R peptides and anti-IL-10 single domain antibodies that stimulate or modulate the immune system and improve gastrointestinal physiology of an animal fed the transgenic plants or tissues thereof and the genes encoding the antagonist IL-10R peptides and anti-IL-10 single domain antibodies are described. The animal feed additives and animal feed incorporating the transgenic plants or tissues thereof are also described. Methods of stimulating or modulating an animal's immune system, improving an animal's gastrointestinal physiology, improving animal performance by using the transgenic plants or tissues thereof, and treating animals infected with a gastrointestinal pathogen are provided.

Methods for producing single N-terminal domain functional camelid-derived heavy (H)-chain antibody fragments (VHH) that specifically bind to a receptor binding domain (RBD) of SARS-CoV-2 spike protein include transgenic plants, plant parts, plant cells, plant tissue, and seeds that express the VHH that specifically binds to an RBD of SARS-CoV-2 spike protein.

The present invention includes compositions and methods of reducing the glycosylation of proteins comprising: obtaining a cell that expresses one or more proteins that comprise one or more glycosylation sites and are glycosylated; expressing in the cell one or more glycosidases that cleaves one or more glycosyl groups from the one or more proteins; and isolating the one or more proteins with reduced glycosylation from the cell.

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

The present invention relates to a method for manufacturing a transgenic plant producing immunogenic complex proteins and immunogenic complex proteins obtained therefrom and, more specifically, to a method for manufacturing a transgenic plant producing immunogenic complex proteins, a plant manufactured by the method, and immunogenic complex proteins obtained from the plant, wherein the method comprises the steps of: (a) manufacturing a transgenic plant expressing an antigen; (b) manufacturing a transgenic plant expressing an antibody specific to the antigen in step (a); and (c) cross-breeding the plants in steps (a) and (b) to manufacture a cross-bred plant. Immunogenic complex proteins can be mass-produced through the method for manufacturing a transgenic plant, comprising steps (a) to (c), and the transgenic plant manufactured by the method, of the present invention. Further, the immunogenic complex proteins (antigen-antibody complex) obtained from the plant have a gigantic four-dimensional structure, thereby having an excellent immune reaction boosting effect, thus exhibiting an excellent antibody producing capacity in a host animal, even without the use of an immune adjuvant.

A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.

A monoclonal secretory IgA antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory IgA antibody is useful in treating a variety of inflammatory diseases in humans.

Disclosed herein are methods of producing a therapeutic plant antibody or fragment thereof, which is produced in a plant or plant cell to provide a plant antibody or fragment thereof that is unable to substantially cross the placenta if administered to a pregnant mother, but that if produced in a mammal or mammalian cell may cross the placenta and potentially result in damage to a foetus or newborn if administered to a pregnant mother, and so is suitable for use in pregnant subjects. The therapeutic plant antibody can also be used in compositions and medicaments for treating various conditions.

Disclosed are monoclonal antibodies against Chikungunya virus having enhanced effector function and efficacy, methods of producing them, and methods of treatment of Chikungunya viral infection using the antibodies.